Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil.
Voskuilen CS, van de Kamp MW, Schuring N, Mertens LS, Noordzij A, Pos F, van Rhijn BWG, van der Heijden MS, Schaake EE. Voskuilen CS, et al. Among authors: van rhijn bwg, van de kamp mw, van der heijden ms. Radiother Oncol. 2020 Sep;150:275-280. doi: 10.1016/j.radonc.2020.07.057. Epub 2020 Aug 6. Radiother Oncol. 2020. PMID: 32768507
Risk factors associated with positive surgical margins' location at radical cystectomy and their impact on bladder cancer survival.
Claps F, van de Kamp MW, Mayr R, Bostrom PJ, Boormans JL, Eckstein M, Mertens LS, Boevé ER, Neuzillet Y, Burger M, Pouessel D, Trombetta C, Wullich B, van der Kwast TH, Hartmann A, Allory Y, Lotan Y, Shariat SF, Zuiverloon TCM, Mir MC, van Rhijn BWG. Claps F, et al. Among authors: van de kamp mw. World J Urol. 2021 Dec;39(12):4363-4371. doi: 10.1007/s00345-021-03776-5. Epub 2021 Jul 1. World J Urol. 2021. PMID: 34196758 Free article.
A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice.
de Ruiter BM, van de Kamp MW, van Steenbergen JPZ, Franckena M, Boormans JL, de Feijter JM, Bins AD, Hulshof MCCM, de Reijke TM, Schaake E, Oddens JR. de Ruiter BM, et al. Among authors: van de kamp mw. Eur Urol Open Sci. 2022 Mar 16;39:7-13. doi: 10.1016/j.euros.2022.02.010. eCollection 2022 May. Eur Urol Open Sci. 2022. PMID: 35528785 Free PMC article.
Survival after neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer.
Einerhand SMH, van Dijk N, van Dorp J, de Feijter JM, van Montfoort ML, van de Kamp MW, Schaake EE, Boellaard TN, Hendricksen K, van der Heijden MS, van Rhijn BWG. Einerhand SMH, et al. Among authors: van de kamp mw. Int J Cancer. 2022 Dec 1;151(11):2004-2011. doi: 10.1002/ijc.34125. Epub 2022 Jun 10. Int J Cancer. 2022. PMID: 35603905 Clinical Trial.
High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.
van Dorp J, Pipinikas C, Suelmann BBM, Mehra N, van Dijk N, Marsico G, van Montfoort ML, Hackinger S, Braaf LM, Amarante T, van Steenis C, McLay K, Daletzakis A, van den Broek D, van de Kamp MW, Hendricksen K, de Feijter JM, Boellaard TN, Meijer RP, van der Heijden AG, Rosenfeld N, van Rhijn BWG, Jones G, van der Heijden MS. van Dorp J, et al. Among authors: van de kamp mw. Nat Med. 2023 Mar;29(3):588-592. doi: 10.1038/s41591-022-02199-y. Epub 2023 Feb 2. Nat Med. 2023. PMID: 36732628 Clinical Trial.
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy.
Claps F, van de Kamp MW, Mayr R, Bostrom PJ, Shariat SF, Hippe K, Bertz S, Neuzillet Y, Sanders J, Otto W, van der Heijden MS, Jewett MAS, Stöhr R, Zlotta AR, Trombetta C, Eckstein M, Mertens LS, Burger M, Soorojebally Y, Wullich B, Bartoletti R, Radvanyi F, Pavan N, Sirab N, Mir MC, Pouessel D, van der Kwast TH, Hartmann A, Lotan Y, Bussani R, Allory Y, van Rhijn BWG. Claps F, et al. Among authors: van de kamp mw. BJU Int. 2023 Aug;132(2):170-180. doi: 10.1111/bju.15984. Epub 2023 Feb 20. BJU Int. 2023. PMID: 36748180 Free article.
Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.
van Dorp J, Pipinikas C, Suelmann BBM, Mehra N, van Dijk N, Marsico G, van Montfoort ML, Hackinger S, Braaf LM, Amarante T, van Steenis C, McLay K, Daletzakis A, van den Broek D, van de Kamp MW, Hendricksen K, de Feijter JM, Boellaard TN, Meijer RP, van der Heijden AG, Rosenfeld N, van Rhijn BWG, Jones G, van der Heijden MS. van Dorp J, et al. Among authors: van de kamp mw. Nat Med. 2024 Jan;30(1):304. doi: 10.1038/s41591-023-02500-7. Nat Med. 2024. PMID: 37460757 No abstract available.
13 results